The CDK4/6 inhibitor palbociclib in a dose and schedule of 125 mg daily for 21 days every 28 days resulted in a median PFS of 17.9 (95% CI, 11.9–24.0) weeks and PFS rate at 12 weeks of 57.2% (95% CI, 42.4–68.8%) in a Phase 2 trial in patients with advanced WDLPS and DDLPS [61]. This evidence concerns the gene CDK4 and dedifferentiated liposarcoma.